Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 2
1968 1
1970 2
1971 1
1972 2
1976 3
1979 1
1981 2
1982 1
1985 2
1986 6
1987 5
1988 6
1989 13
1990 17
1991 20
1992 14
1993 17
1994 16
1995 26
1996 24
1997 35
1998 26
1999 24
2000 24
2001 30
2002 29
2003 50
2004 53
2005 49
2006 54
2007 51
2008 50
2009 59
2010 65
2011 91
2012 84
2013 80
2014 61
2015 55
2016 55
2017 55
2018 56
2019 22
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

1,231 results
Results by year
Filters applied: . Clear all
Page 1
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, Cheng Q, Li Q. Wang K, et al. Kidney Blood Press Res. 2018;43(3):768-779. doi: 10.1159/000489913. Epub 2018 May 22. Kidney Blood Press Res. 2018. PMID: 29794446 Free article. Review.
The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.
Saglimbene V, Palmer SC, Ruospo M, Natale P, Maione A, Nicolucci A, Vecchio M, Tognoni G, Craig JC, Pellegrini F, Lucisano G, Hegbrant J, Ariano R, Lamacchia O, Sasso A, Morano S, Filardi T, De Cosmo S, Pugliese G, Procaccini DA, Gesualdo L, Palasciano G, Johnson DW, Tonelli M, Strippoli GFM; Long-Term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) Investigators. Saglimbene V, et al. J Am Soc Nephrol. 2018 Dec;29(12):2890-2899. doi: 10.1681/ASN.2018040443. Epub 2018 Nov 12. J Am Soc Nephrol. 2018. PMID: 30420421 Free PMC article. Clinical Trial.
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Cherney DZI, et al. Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621. doi: 10.1016/S2213-8587(17)30182-1. Epub 2017 Jun 27. Lancet Diabetes Endocrinol. 2017. PMID: 28666775
Menopause and Chronic Kidney Disease.
Ahmed SB. Ahmed SB. Semin Nephrol. 2017 Jul;37(4):404-411. doi: 10.1016/j.semnephrol.2017.05.013. Semin Nephrol. 2017. PMID: 28711080 Review.
Treatment of Hypertension Induced Albuminuria.
Knežević T, Gellineo L, Jelaković A, Premužić V, Dika Ž, Laganović M, Jelaković B. Knežević T, et al. Curr Pharm Des. 2018;24(37):4404-4412. doi: 10.2174/1381612825666181126170354. Curr Pharm Des. 2018. PMID: 30479206
Diabetic Nephropathy: From Pathophysiology to Treatment.
Shen Z, Fang Y, Xing T, Wang F. Shen Z, et al. J Diabetes Res. 2017;2017:2379432. doi: 10.1155/2017/2379432. Epub 2017 Oct 23. J Diabetes Res. 2017. PMID: 29201920 Free PMC article. No abstract available.
1,231 results
Jump to page
Feedback